Biomolecular Events in Cancer Revealed by Attractor Molecular Signatures
Patent Number: US20160312289A1
Executive Summary:
General Description:
This technology may more precisely identify specific genetic biomarkers of anomalous biological mechanisms. The metagenes derived by this process may be used to develop more accurate tools for cancer diagnosis and treatment. Additionally, this technology may further clarify the biological mechanisms underlying such diseases and enable the more efficient discovery of relevant therapeutic targets.
Scientific Progress:
The algorithm was validated using nearly 2,000 breast cancer samples and its predictions were shown to outperform those from current commercially available breast cancer genetic kits.
Future Directions:
Strengths:
Weaknesses:
Patent Status:
Legal status: Pending
Publication PMID: 23468608, 25249324, 23596202
Publications:
Cheng WY, Ou Yang TH, Anastassiou D. Biomolecular Events in Cancer Revealed by Attractor Metagenes. PLoS Comput Biol. 2013;9(2):e1002920.
Ou Yang TH, Cheng WY, Zheng T, Maurer MA and Anastassiou D. Breast Cancer Prognostic Biomarker Using Attractor Metagenes and the FGD3-SUSD3 Metagene. Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2850-6.
Cheng WY, Ou Yang TH, Anastassiou D. Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge Environment. Sci Transl Med. 2013 Apr 17;5(181):181ra50.
Inventor Bio: Dimitris Anastassiou
https://biology.columbia.edu/labaffiliation/anastassiou-lab
Executive Summary:
- Invention Type: Diagnostic
- Patent Status: Pending
- Patent Link: https://patents.google.com/patent/US20160312289A1
- Related Patent Link: https://patents.google.com/patent/WO2014193522A1
- Research Institute: Columbia University
- Disease Focus: Brain tumors
- Basis of Invention: This technology is an algorithm that identifies metagenes – linear combinations of individual genes – that are biomarkers for the specific underlying biological mechanisms of a disease
- How it works: This technology consists of an iterative algorithm that starts at a seed gene and converges on a metagene, which serves as a reliable biomarker for a specific biological mechanism that is characteristic of a larger disease. This technology isolates the specific genes that represent a single, specific disease phenotype (e.g. cell transdifferentiation or the presence of an amplicon)
- Lead Challenge Inventor: Dimitris Anastassiou
- Development Stage: Preclinical
- Novelty:
- Powerful tool for mining large, publicly available gene expression data sets
- Clinical Applications:
- Method to mine data for genetic biomarkers of specific disease phenotypes
- Identification of biomarkers that can assist in the personalized diagnosis, prognosis, and choice of treatment for a given disease
- Research tool to help understand the biological mechanisms behind a disease and improve drug target discovery
General Description:
This technology may more precisely identify specific genetic biomarkers of anomalous biological mechanisms. The metagenes derived by this process may be used to develop more accurate tools for cancer diagnosis and treatment. Additionally, this technology may further clarify the biological mechanisms underlying such diseases and enable the more efficient discovery of relevant therapeutic targets.
Scientific Progress:
The algorithm was validated using nearly 2,000 breast cancer samples and its predictions were shown to outperform those from current commercially available breast cancer genetic kits.
Future Directions:
- Clinical validation in brain tumor patients
Strengths:
- Even large numbers of metagenes are easily viewable in a linear format
- Metagenes group together only the most pertinent individual genes extracted from large data sets of gene expression profiles
- No prior knowledge of gene function or gene interaction is needed
- Metagenes can accurately portray a single phenotype or biological mechanism that occurs during the course of a given disease
Weaknesses:
- Not yet tested in brain tumor patients
Patent Status:
Legal status: Pending
- Priority date: 2013-05-29
- Filing date: 2015-11-25
- Publication date: 2016-10-27
Publication PMID: 23468608, 25249324, 23596202
Publications:
Cheng WY, Ou Yang TH, Anastassiou D. Biomolecular Events in Cancer Revealed by Attractor Metagenes. PLoS Comput Biol. 2013;9(2):e1002920.
Ou Yang TH, Cheng WY, Zheng T, Maurer MA and Anastassiou D. Breast Cancer Prognostic Biomarker Using Attractor Metagenes and the FGD3-SUSD3 Metagene. Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2850-6.
Cheng WY, Ou Yang TH, Anastassiou D. Development of a Prognostic Model for Breast Cancer Survival in an Open Challenge Environment. Sci Transl Med. 2013 Apr 17;5(181):181ra50.
Inventor Bio: Dimitris Anastassiou
https://biology.columbia.edu/labaffiliation/anastassiou-lab
